TWI831797B - 靶向adam9之免疫接合物及其使用方法 - Google Patents

靶向adam9之免疫接合物及其使用方法 Download PDF

Info

Publication number
TWI831797B
TWI831797B TW108122055A TW108122055A TWI831797B TW I831797 B TWI831797 B TW I831797B TW 108122055 A TW108122055 A TW 108122055A TW 108122055 A TW108122055 A TW 108122055A TW I831797 B TWI831797 B TW I831797B
Authority
TW
Taiwan
Prior art keywords
seq
ala
adam9
domain
cdr
Prior art date
Application number
TW108122055A
Other languages
English (en)
Chinese (zh)
Other versions
TW202019960A (zh
Inventor
史都華 威廉 希克斯
尼可拉斯 C 優得
巴斯瓦提 巴拉特
艾吉歐 波維尼
鋼多 狄瑞奇
雷斯理 S 強森
德利 盧
強尼普 A 史納
Original Assignee
美商伊繆諾金公司
美商宏觀基因股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商伊繆諾金公司, 美商宏觀基因股份有限公司 filed Critical 美商伊繆諾金公司
Publication of TW202019960A publication Critical patent/TW202019960A/zh
Application granted granted Critical
Publication of TWI831797B publication Critical patent/TWI831797B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW108122055A 2018-06-26 2019-06-25 靶向adam9之免疫接合物及其使用方法 TWI831797B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862690052P 2018-06-26 2018-06-26
US62/690,052 2018-06-26
US201862691342P 2018-06-28 2018-06-28
US62/691,342 2018-06-28
US201962810703P 2019-02-26 2019-02-26
US62/810,703 2019-02-26

Publications (2)

Publication Number Publication Date
TW202019960A TW202019960A (zh) 2020-06-01
TWI831797B true TWI831797B (zh) 2024-02-11

Family

ID=67513726

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108122055A TWI831797B (zh) 2018-06-26 2019-06-25 靶向adam9之免疫接合物及其使用方法

Country Status (13)

Country Link
US (1) US20210275685A1 (cg-RX-API-DMAC7.html)
EP (1) EP3814378A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021528471A (cg-RX-API-DMAC7.html)
KR (1) KR20210061995A (cg-RX-API-DMAC7.html)
CN (1) CN112543770A (cg-RX-API-DMAC7.html)
AU (1) AU2019294510A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020025346A2 (cg-RX-API-DMAC7.html)
CA (1) CA3104511A1 (cg-RX-API-DMAC7.html)
IL (1) IL279633A (cg-RX-API-DMAC7.html)
MX (1) MX2020013466A (cg-RX-API-DMAC7.html)
SG (1) SG11202012257VA (cg-RX-API-DMAC7.html)
TW (1) TWI831797B (cg-RX-API-DMAC7.html)
WO (1) WO2020005945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020240310A1 (en) 2019-03-21 2021-10-07 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
JP2024512392A (ja) 2021-03-08 2024-03-19 イミュノジェン・インコーポレーテッド がんの治療のためのadam9を標的とする免疫抱合体の有効性を増加させるための方法
WO2024059263A1 (en) * 2022-09-15 2024-03-21 Immunogen, Inc. Methods for preparing maytansinoid derivatives with self-immolative peptide linkers
TWI876557B (zh) * 2022-09-30 2025-03-11 臺北醫學大學 用於前列腺癌診斷和早期發病的單株抗體
EP4692118A1 (en) * 2023-03-24 2026-02-11 Duality Biologics (Shanghai) Co., Ltd. Adam9-targeting humanized antibody and antibody-drug conjugate comprising same and use thereof
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
CN120058950A (zh) * 2023-11-28 2025-05-30 昆山新蕴达生物科技有限公司 抗adam9的抗体及其用途
CN122422348A (zh) * 2023-12-14 2026-07-17 四川科伦博泰生物医药股份有限公司 Adam9结合蛋白及其用途
WO2026102182A1 (en) * 2024-11-06 2026-05-15 Ossianix, Inc. A vnar-based brain shuttle for payload conjugation and gene therapy

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US20030091568A1 (en) 2000-04-07 2003-05-15 Jurgen Frey Inhibitors for the formation of soluble human CD23
EP1142910A1 (en) 2000-04-07 2001-10-10 Jürgen Prof. Dr. Frey Inhibitors for the formation of soluble human CD23
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20060270618A1 (en) 2001-12-18 2006-11-30 Dorian Bevec Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040092466A1 (en) 2002-11-11 2004-05-13 Isis Pharmaceuticals Inc. Modulation of ADAM9 expression
EP1542723B1 (en) 2002-08-16 2011-02-23 ImmunoGen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
DE10337368A1 (de) * 2003-08-08 2005-03-03 Technische Universität Dresden Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US7829277B2 (en) 2004-03-01 2010-11-09 The Regents Of The University Of California Methods for identifying compounds that suppress chemically-induced carcinogenesis
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP5328155B2 (ja) 2005-02-02 2013-10-30 マクロジェニックス ウエスト, インコーポレイテッド Adam−9モジュレータ
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
WO2007143752A2 (en) 2006-06-09 2007-12-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
KR101443214B1 (ko) 2007-01-09 2014-09-24 삼성전자주식회사 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
US8101361B2 (en) 2008-03-10 2012-01-24 National Jewish Health Markers for diagnosis of pulmonary inflammation and methods related thereto
WO2009126616A2 (en) 2008-04-07 2009-10-15 Zymogenetics, Inc. Thrombin activator compostions and methods of making and using the same
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US20110129450A1 (en) 2008-08-01 2011-06-02 Orly Lazarov Method of promoting neurogenesis by modulating secretase activities
WO2010053539A2 (en) 2008-11-05 2010-05-14 The Texas A&M University System Methods for detecting colorectal diseases and disorders
SG171812A1 (en) 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102596922A (zh) * 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
MX2012004406A (es) * 2009-10-21 2012-05-08 Immunogen Inc Nuevo regimen de dosificacion y metodo de tratamiento.
CA2789679A1 (en) 2010-02-11 2011-08-18 University Of Southern California Modified adam disintegrin domain polypeptides and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US20130130355A1 (en) 2011-09-28 2013-05-23 Armune Biosciences, Inc. Method and system of particle-phage epitope complex
IN2014CN04935A (cg-RX-API-DMAC7.html) 2011-12-31 2015-09-18 Moni Abraham Kuriakose
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
CA2897340C (en) 2013-01-09 2022-09-06 Friedrich-Alexander-Universitat Erlangen-Nuernberg Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles
HK1218930A1 (zh) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc 新型多特异性结构
EP3964237B1 (en) * 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
JPWO2014168154A1 (ja) 2013-04-08 2017-02-16 三菱レイヨン株式会社 眼疾患を評価するためのマイクロアレイ及び眼疾患の評価方法
ES2902420T3 (es) 2013-05-13 2022-03-28 Univ Tufts Composiciones para el tratamiento del cáncer que expresa ADAM8
US20160138113A1 (en) 2013-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis
US9567641B2 (en) 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
WO2016077505A2 (en) 2014-11-11 2016-05-19 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
TW201731532A (zh) * 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
MD3558391T2 (ro) * 2016-12-23 2022-05-31 Immunogen Inc Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Hicks et al., "Abstract 37: Novel antibody-drug conjugates targeting ADAM9-expressing solid tumors demonstrate potent preclinical activity", Cancer Research, 2017, 77(13_Supplement): 37.
期刊 Scribner et al., "Abstract 38: Target validation, antibody discovery and preclinical data supporting ADAM9 as an antibody-drug conjugate therapeutic target for solid tumor", Cancer Research, 2017, 77(13_Supplement): 38.

Also Published As

Publication number Publication date
SG11202012257VA (en) 2021-01-28
WO2020005945A1 (en) 2020-01-02
TW202019960A (zh) 2020-06-01
BR112020025346A2 (pt) 2021-05-25
US20210275685A1 (en) 2021-09-09
AU2019294510A1 (en) 2021-01-21
KR20210061995A (ko) 2021-05-28
CA3104511A1 (en) 2020-01-02
AU2019294510A8 (en) 2021-04-22
MX2020013466A (es) 2021-04-19
JP2021528471A (ja) 2021-10-21
IL279633A (en) 2021-03-01
EP3814378A1 (en) 2021-05-05
CN112543770A (zh) 2021-03-23

Similar Documents

Publication Publication Date Title
TWI783957B (zh) 靶向adam9之免疫共軛物及其使用方法
TWI897855B (zh) E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
KR102434626B1 (ko) 항-b7-h3 항체 및 항체 약물 콘쥬게이트
TW202019960A (zh) 靶向adam9之免疫接合物及其使用方法
KR20180130574A (ko) 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
JP2025524628A (ja) Epcamイムノコンジュゲート及びその使用
KR20250089499A (ko) Napi2b를 표적화하는 항체-약물 접합체 및 사용 방법
CN115484982A (zh) 用于单独或组合使用b7-h3抗体-药物缀合物的方法
TW202430557A (zh) Anti-Met抗體、抗體藥物偶聯物及其製備方法和用途
KR20250089514A (ko) 글리피칸-3을 표적화하는 항체-약물 접합체 및 사용 방법
HK40015128B (en) Immunoconjugates targeting adam9 and methods of use thereof
HK40015128A (en) Immunoconjugates targeting adam9 and methods of use thereof
JP2025531990A (ja) c-Metを標的とする抗体薬物コンジュゲート及び使用方法
TW202602943A (zh) 抗trop2抗體藥物偶聯物及使用方法
TW202448517A (zh) 用治療性結合分子治療癌症的組合療法

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees